Interestingly, this benefit was not observed when the combinatorial treatment was tested on spheroids derived from mouse lung cancer cells with genetically modified TP53 and KRAS (Supplementary Fig. 10) suggesting this improved efficacy is specific to H1819 and H460 as indicated by their transcriptional profiling. Here, TP53 is linked to lung cancer.